Gene therapy with AdV-IL2 (TG 1021) in unresectable digestive adenocarcinoma. Phase I-II study, first inclusions.
Gilly FN, Sayag-Beaujard AC, Bienvenu J, Aymard M, Touraine-Moulin F, Favrot M, Trillet-Lenoir V, Pavirani A, Courtney M, François Y, Pellet O, Gaillard C, Glehen O, Banssillon V, Vignal J, Ross M.
Gilly FN, et al.
Adv Exp Med Biol. 1998;451:527-30. doi: 10.1007/978-1-4615-5357-1_81.
Adv Exp Med Biol. 1998.
PMID: 10026922
Clinical Trial.
No abstract available.